Baxter International Inc Stock News

WASHINGTON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Chemotherapy Devices Market finds that increasing prevalence of cancer is expediting market growth. Primarily driven by increasing cardiovascular surgeries and diagnostics, the total Global Chemotherapy Devices Market is estimated to reach USD 23.12 Billion by 2028 . The Market stood at a revenue of USD 11.54 Billion in the year 2021, and is expected to exhibit a Compound Annual Growth Rate (CAGR) of 7.5%. Furthermore, the increase in technological advancements is also anticipated to augment the growth of the Global Chemotherapy Devices Market, states Vantage Market Research, in a report, titled " Chemotherapy Devices Market by Product (Catheter, Cannula, Pump, Others), by Application (Hospital, Clinics, Home Care), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)". Click Here To Access The Free Sample Report @ https://www.vantagemarketresearch.com/chemotherapy-devices-market-1310/request-sample (The Free Sample Of This Report Is Readily Available On Request).

Over the past 3 months, 6 analysts have published their opinion on Baxter Intl (NYSE: BAX ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 6 0 0 0 Last 30D 0 3 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 3 0 0 0 3M Ago 0 0 0 0 0 According to 6 analyst offering 12-month price targets in the last 3 months, Baxter Intl has an average price target of $100.5 with a Full story available on Benzinga.com

The Baxter (NYSE: BAX) stock is trending today. This is why.

Baxter International Inc (NYSE: BAX ) has posted Q4 revenue of $3.5 billion , beating the consensus of $3.35 billion, up 10% on a reported basis, 12% on a constant currency basis, and 4% on an operational basis. Adjusted EPS of $1.04 increased 30%, marginally ahead of the consensus of $1.03. Following Baxter''s acquisition of Hillrom, Baxter''s Q4 and FY21 results include Hillrom''s financial … Full story available on Benzinga.com

Shares of Baxter International (BAX) are down 3% in premarket trading even though the company quarterly results beat on the top and bottom lines.

Baxter Earnings, Revenue Beat in Q4

Baxter International's (BAX) CEO Joe Almeida on Q4 2021 Results - Earnings Call Transcript

Baxter press release (BAX): Q4 Non-GAAP EPS of $1.04 beats by $0.01.Revenue of $3.51B (+9.7% Y/Y) beats by $160M.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2021, and provided its financial guidance for full-year and first-quarter 2022. Fourth-quarter and full-year 2021 results reflect 19 days of contribution from Hillrom Holdings, Inc. (Hillrom) subsequent to Baxter’s acquisition of the company on Dec. 13, 2021. “In 2021, Baxter’s dedicated employees remained focused on respondi

Baxter's (BAX) fourth-quarter results reflect robust performance across six of its business units.

Baxter International Inc (NYSE: BAX) has posted Q4 revenue of $3.5 billion, beating the consensus of $3.35 billion, up 10% on a reported basis, 12% on a constant currency basis, and 4% on an operati

Baxter (BAX) delivered earnings and revenue surprises of 0.97% and 4.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

New York, USA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Orthobiologics Market is Anticipated to Grow at a CAGR of 4.44% During the Forecast Period (2021-26) | DelveInsight As per DelveInsight analysis, a growing geriatric population at risk of developing various bone degenerative disorders, an increase in traumatic injuries such as car accidents, sports injuries, and others are expected to boost the Orthobiologics market growth. Furthermore rising investments in R&D and collaborations by key manufacturers, as well as an increase in various orthobiologic product approvals will also drive the market. DelveInsight''s Orthobiologics Market Insights and Forecast report provides the current and forecast Orthobiologics market, upcoming developments in the medical devices, individual market shares, challenges, drivers, barriers, market growth trends, and key players in the Orthobiologics market. Some of the Key Highlights from the Orthobiologics Market Report According to DelveInsight analysis, North America is expected to dominate the overall Orthobiologics Market during the forecasted period.